Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
12/09/16 1:54 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting 12/05/16Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting 12/05/16
EventsInvestor and Analyst Event at the American Society of Hematology (ASH) Annual Meeting12/05/16 8:15 p.m. PTView eventCredit Suisse 25th Annual Healthcare Conference11/08/16 12:00 p.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|